SCHEMBL223317

SCHEMBL223317

CC(O)CNC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 1/20 0.46
CYP2D6 P10635 1/20 0.45
CTSS P25774 3/20 0.44
CTSK P43235 3/20 0.44
CTSL P07711 2/20 0.44
CTSB P07858 1/20 0.44
SYK P43405 1/20 0.41
SERPINE1 P05121 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
PCSK9 Q8NBP7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
APLNR P35414 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348464 1.00 MEN1 (0.49) MEN1GAAKMT2ATDP1CA1
SCHEMBL347096 1.00 MEN1 (0.49) MEN1GAAKMT2ATDP1CA1
SCHEMBL25381545 0.93 TDP1 (0.46) MEN1GAAKMT2ATDP1CA1
SCHEMBL15069849 0.87 MEN1 (0.42) MEN1GAAKMT2ATDP1CA1
SCHEMBL1105702 0.85 PCSK9 (0.50) MEN1GAAKMT2ATDP1CA1
SCHEMBL6563149 0.85 MEN1 (0.50) MEN1GAAKMT2ATDP1CA1
SCHEMBL570033 0.85 MEN1 (0.50) MEN1GAAKMT2ATDP1CA1
SCHEMBL18495370 0.85 MEN1 (0.50) MEN1GAAKMT2ATDP1CA1
SCHEMBL22731060 0.85 MEN1 (0.44) MEN1GAAKMT2ATDP1CA1
SCHEMBL21202376 0.84 MEN1 (0.47) MEN1GAAKMT2ATDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3941459-B1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2026-05-06 EP disclosed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
EP-4396191-B1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2026-02-18 EP disclosed
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 US disclosed
EP-4663205-A1 POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF Shanghai Best-Link Bioscience, LLC (CN) 2025-12-17 EP disclosed
US-20250352662-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS INC (US) 2025-11-20 US disclosed
EP-4637833-A2 CEREBLON DEGRADER CONJUGATES, AND USES THEREOF Genentech, Inc. (US) 2025-10-29 EP disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 US disclosed
US-12440576-B2 Antibody drug conjugates comprising sting agonists MERSANA THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 US disclosed
EP-0595995-B1 ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1997-01-15 EP disclosed
US-5514702-A Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity ABBOTT LABORATORIES (US) 1996-05-07 US disclosed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN disclosed
EP-0629617-A1 Heteroatom-bearing ligands and metal complexes thereof BRACCO International B.V. (NL) 1994-12-21 EP disclosed
EP-0595995-A4 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1994-08-24 EP disclosed
EP-0595995-A1 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. ABBOTT LAB (US) 1994-05-11 EP disclosed
US-5214204-A Inhibitors of biosynthesis of leukotrienes ABBOTT LABORATORIES (US) 1993-05-25 US disclosed
WO-1993002037-A1 ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1993-02-04 WO disclosed
US-4943567-A EFFECTIVE AGAINST PSEUDOMONAS KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-07-24 US disclosed
EP-0293771-A2 Cephalosporin compound and pharmaceutical composition thereof Kyoto Pharmaceutical Industries, Ltd. (JP) 1988-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12440576-B2 Antibody drug conjugates comprising sting agonists STING1, CGAS, IFNAR1 MEN1 3115/4885GAA 352/4885KMT2A 2297/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 MEN1 947/4885GAA 4095/4885KMT2A 479/4885
US-20250352662-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 MEN1 3115/4885GAA 352/4885KMT2A 2297/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 MEN1 2646/4885GAA 2539/4885KMT2A 1758/4885
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP3, DPP7, DPP9 MEN1 3217/4885GAA 373/4885KMT2A 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.